In a phase 1/2 study, ensartinib was generally well tolerated and demonstrated good clinical activity in pts with ALK+ non-small cell lung cancer (NSCLC). This post hoc analysis sought to determine the relationship between ensartinib-related rash and clinical benefit. The study found that ensartinib was associated with mild to moderate rash that was easily managed. Preliminary findings suggest that rash is potentially associated with better clinical benefit with ensartinib. READ ARTICLE
Journal of Thoracic Oncology DOI:10.1016/j.jtho.2019.08.1183
Authors: H. Wakelee, K. Reckamp, T. Leal, A. Chiappori, S. Waqar, K. Zeman, J. Neal, C. Liang, K. Harrow, A. Holzhausen, J. Zhou, G. Selvaggi, L. Horn
